Abbott Laboratories (ABT) earnings on July 16, 2026
More Abbott Laboratories earnings
Prior outlook: Optimistic Outcome: Accurate
Abbott Labs shares jumped after the company raised its outlook and eased concerns about procedure volumes.
ABT price around the earnings
98.83
Change: +10.7%
2026-07-16, 20:00 UTC
Start of the measured window
End of the measured window
89.00
93.25
97.50
101.75
89.27
July 16, 2026
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Accurate
- Thesis published
Analyst upside strong (+30.5%) but negative quarterly earnings growth and minimal past surprise temper outlook.
Context analyzed before publication
- Trend
- Volatile trajectory, initially collapsing then recovering to a positive score into earnings.
Analysts
Evidence
- Analyst consensus
- Buy
- Consensus average (1-5)
- 1.67
- Analysts covering the stock
- 24
- Average price target
- 116.54
- Lowest price target
- 92
- Highest price target
- 135
- Upside to price target
- 30.5%
- Quarterly earnings growth
- -18.7%
- Revenue growth
- 7.8%
- Forward EPS
- 6.06
- Trailing EPS
- 3.57
- Analyst moves in the last 60 days
- 3
- Strong buy: 4
- Buy: 16
- Hold: 7
- Sell: 0
- Strong sell: 0
- Strong buy
- 4
- Buy
- 16
- Hold
- 7
- Sell
- 0
- Strong sell
- 0
- July 6, 2026 · Evercore ISI Group: Maintains rating (Outperform → Outperform)
- July 1, 2026 · Baird: Initiates coverage (Outperform)
- June 22, 2026 · Piper Sandler: Reiterates rating (Overweight → Overweight)
News and sentiment
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- Low
- Normalized volume
- 33%
News
Sources (7)
- UnitedHealth, Abbott Laboratories And 3 Stocks To Watch Heading Into Thursday — Benzinga
- Evercore ISI Group Maintains Outperform on Abbott Laboratories, Lowers Price Target to $112 — Benzinga
- FDA Approves Abbott HIV Combo Next Assay Under 510(k) BK261345 On June 29, 2026 — Benzinga
- This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday — Benzinga
- Baird Initiates Coverage On Abbott Laboratories with Outperform Rating, Announces Price Target of $121 — Benzinga
- Abbott Signs Licensing Agreement With ALZpath, A Provider Of Blood-Based Diagnostics For Alzheimer's, For Its Proprietary Phosphorylated Tau 217 Antibody — Benzinga
- Piper Sandler Reiterates Overweight on Abbott Laboratories, Maintains $115 Price Target — Benzinga
Technicals
Evidence
- Average true range (ATR)
- 2.7%
- Distance to 52-week high
- -33.1%
- 14-day change (14d)
- -1.4%
- 30-day change (30d)
- +1.7%
- 30-day relative strength
- +1.7%
- Benchmark change (0d)
- +0.0%
- Nearest support
- 89.2
- Nearest resistance
- 89.59
- Volume accumulation ratio (14d / 46d)
- 0.97
Trends
Evidence
- Average earnings surprise
- +0.3%
- April 16, 2026: actual EPS 1.15 vs estimate 1.15 (surprise +0.3%)
- January 22, 2026: actual EPS 1.5 vs estimate 1.49 (surprise +0.3%)
- October 15, 2025: actual EPS 1.3 vs estimate 1.3 (surprise +0.1%)
- July 17, 2025: actual EPS 1.26 vs estimate 1.26 (surprise +0.3%)
Expected move
There is no implied-move data available for this event.
Reactions over its last 20 earnings
- Median move
- 3%
- 75th percentile move
- 4.8%
- 90th percentile move
- 7.9%
- Up / down moves
- 8 / 12
- Average up move
- +3.3%
- Average down move
- -4.2%
Monitoring and close
What Abbott Laboratories reported
There is no monitoring data available for this event.
Pre-market second reading after the results
There is no second reading available for this event.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- +10.7%
- Max favorable move (MFE)
- 14.1%
- Max adverse move (MAE)
- 1%